Objectives: To provide a foundation for the diagnostic, prophylactic and therapeutic management of febrile neutropenia and sepsis in children with oncological diseases, with special attention to new protocols and guidelines. 
Introduction
Over the last 10 years a large number of publications have attempted to provide safe and consolidated guidelines for the diagnosis and treatment of pediatric oncology patients with febrile neutropenia, infection, sepsis, septic shock and organ and system dysfunction. 1, 2 They are justified by their importance, since these conditions constitute the principal cause of mortality in children with cancer, and the primary reason for indicating intensive care, both among those who are cured and those who die as a result of oncological diseases. 3 The approach taken by the majority of protocols generally focuses on adult patients and does not dwell on questions that involve the pediatric population specifically. 4, 5 In order to be safe, clinical management of febrile neutropenia, infection and sepsis in pediatric oncology must take into account specific issues that involve this population. This review aims to provide a basis for the etiology, diagnosis and prophylactic and therapeutic approach to febrile neutropenia and infection and to the diagnosis and treatment of sepsis in children with varying types of cancer.
Epidemiological studies demonstrate a high prevalence of sepsis among these children, with 12.8% of cases of sepsis in children aged 1-9 years affecting children with cancer, with an even higher incidence (17.4%) among those aged [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] years. Furthermore, while lethality is 10% in the general population, among cancer patients this number reaches
16%. There appears to be a clear difference in children who undergo bone marrow transplant, a group with a much higher mortality rate in the majority of case series. 6 Additionally, among patients with lymphoma/leukemia, there is an increased predisposition towards development of septic conditions, when compared with solid tumors, perhaps because of the use of more aggressive myeloablative therapy.
In addition to the type of cancer, the disease stage and the treatment given have an influence on the predisposition towards sepsis. Children on intensive chemotherapy protocols have a six times greater chance of developing sepsis than more conservative protocols. In a previous study, involvement of the bone marrow increased the odds ratio for sepsis to 2.4 (95%CI 1.3-4.6). 7 Circulatory shock is clearly a factor for poor prognosis among these children. Other clinical signs, such as positive blood cultures, temperature > 39 ºC and extended capillary refill time, are also indicative of the need to employ intensive care resources. 8 The intensity of neutropenia and its duration have been demonstrated in many studies as predictive of the development of infectious complications and sepsis, deserving specific protocol led management. 
Neutropenia
This describes a total neutrophil count < 500/μL or < 1,000/μL, with decline predicted over the next 2 days.
1,2
The severity of neutropenia in terms of the risk of infection is related to the total number of neutrophils, with greatest risk of infection considered to affect those who have a global count ≤ 100 neutrophil/μL. Table 2 : polymerase chain reaction (PCR) ≥ 90 mg/L, arterial hypotension, relapsed leukemia, platelet count < 50,000/mm 3 and an interval < 7 days between the end of the last chemotherapy cycle and onset of fever. These variables exhibited sensitivity, specificity, positive predictive value and negative predictive value of 92, 76, 82 and 90%, respectively. The research identified variables that are easy to acquire and can be used the first time the patient is seen with no need for an advanced technological Arsenal ( Table 2) .
Diagnostic approach
During the initial diagnostic approach to these patients, clinical workup should be systematically applied in a complete manner, giving special attention to scheme, mucosa and hair and nails, the genital, anal and oral areas, 
Group Definition
Low risk Duration of neutropenia ≤ 5 days, in the absence of any factor listed in Table 2 Intermediate risk Duration of neutropenia between 6 and 9 days
High risk Duration of neutropenia ≥ 10 days 
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Blood culture
Preferably, two samples should be taken from a peripheral vein, with a 20-minute interval and from two different sites.
When a central venous catheter (CVC) is in place, a sample should be taken from it, and another from a peripheral vein.
In these cases, bacterial growth observed in the CVC sample 2 hours or more before it occurs in the other sample suggests that the catheter is the site of infection.
11
Urine culture
Indicated in the presence of urinary symptoms 2 or in cases where neoplasms are located in urinary or renal areas.
Cultures of wound secretions
By puncture (preferable) or swab, they should be taken when present from the site of catheter insertion, the site of surgery or mucocutaneous injuries. 
Chest X-ray
Previously chest X-rays were used as criteria of severity in children with febrile neutropenia, however, their value was called into question in recent work by Renoult et al. 15 in that study, pneumonia was the cause of fever in 5% of neutropenic febrile children, and at just 1% of pneumonias exhibited an absence of respiratory symptoms. This being so, chest X-rays on admission can safely be reserved for patients with respiratory abnormalities. Added to that finding is the factor that, as neutrophils are reduced, the inflammatory infiltrate capable of generating radiological images of consolidation are scarcer, which could reduce the sensitivity of the test.
However, it is still worth pointing out, that abnormal x-ray findings are a strong indication of pulmonary involvement in this group of patients. 
Etiology
The majority episodes of febrile neutropenia are treated empirically without identifying the site or etiologic agent, as fever of indeterminate origin. 16 [18] [19] [20] In Brazil, a study carried out with febrile neutropenic patients with chronic lymphoid leukemia revealed that the most common pathogens were capsulated germs (Streptococcus pneumonia, Haemophilus influenzae), S.
aureus and gram-negative enteric bacteria. 21 Other etiologic agents, such as fungi and mycobacteria, may affect, with lower frequency, febrile neutropenic patients and are normally related to more severe and prolonged episodes of neutropenia (neutrophil < 500/μL and neutropenia for more than 10 days), to previous and prolonged wide spectrum antimicrobial use or antifungal prophylaxis and bone marrow or hematopoietic stem cell transplantation. 21 In these patients, fever that persists even when adequate empirical antibiotic therapy is started and the Other therapeutic options with a wider spectrum and an action against strains resistant to fluconazole, include amphotericin B, echinocandins (caspofungin) and new azoles (voriconazole or posaconazole). 22, 25, 26 In relation to amphotericin B, whenever possible, preference should be given to lipid formulae, both because of their lower toxicity and because the original amphotericin B desoxycholate is no longer on the pharmaceutical market.
Whatever the method for stepping up treatment, the attempts to identify the etiologic agent must be sustained, by means of microbiological, serological and molecular biology tests. Furthermore, once the agent is diagnosed, treatment should be stepped down and, wherever the patient's status allows, only those drugs used to treat the agent identified should be maintained.
More recently, in addition to the antimicrobial treatment, attempts are now made to improve patients' immunity. The drug most often used for this is granulocyte stimulating factor. 27 This substance acts on bone marrow stem cells, increasing the population of granulocytes and neutrophils.
The problem with this would be stimulation of neoplastic cells.
The current recommendation of the Children's Oncology
Group is to use this medication for severe leucopenia where there is risk of death (sepsis and septic shock). 
Management of septic shock
Children with oncological disease should be given the therapeutic conduct for septic shock recommended by the recent septic shock task force guidelines, 29 as defined in the algorithm below.
Management of blood hemostasis disturbances
Hemorrhagic disturbances and thrombosis are common complications in children with cancer when in infectious or septic states. 30 Bleeding is more common with leukemia, and 
Management of thrombocytopenia
Several factors may be responsible for the development of thrombocytopenia in children with cancer, such as invasion of the bone marrow, chemotherapy, radiation, sepsis and disseminated intravascular coagulation. 32 The principal clinical manifestation is bleeding from mucosas, petechiae, ecchymosis, epistaxis, gastrointestinal and urogenital bleeding. Usually spontaneous bleeding does not occur, unless platelets fall below 20,000/mm 3 . Some studies have reported that levels of 5,000-10,000/mm 3 are safe in leukemia patients receiving chemotherapy. Table 3 
